DeutschNewstral
Article
bizjournals.com on 2019-03-01 14:08
Shares of Waltham drugmaker ImmunoGen crater after late-stage trial fail
Related news
- Drugmaker with new Waltham offices vows to fight FDA rejectionbizjournals.com
- Latest drug by Waltham drugmaker Tesaro rejected by FDAbizjournals.com
- Drugmaker Alkermes confirms expansion, hiring plans in Walthambizjournals.com
Drugmaker AbbVie to spend over $10 billion on ImmunoGen to juice its cancer-fighting treatment portfoliopressherald.com- CWalthamcbcmagazine.com
- Waltham drugmaker Chiasma cuts another 20 employees in bid to conserve cashbizjournals.com
- Activist investor pushes for ex-Goop CEO, others to join board of Waltham drugmaker Amagbizjournals.com
- Feds freeze Waltham firm's late-stage trial of potential Alzheimer's drugbizjournals.com
- Pending ovarian cancer drug news from ImmunoGen could be a turning pointbizjournals.com
- ImmunoGen impresses investors in Q2, lays out options to raise cashbizjournals.com
- ImmunoGen gains momentum as ovarian cancer drug is set to begin pivotal trialbizjournals.com
ImmunoGen, Inc. v. Hirshfeld (Fed. Cir. 2022)jdsupra.com
Waltham man missing Corvette rimsAustin Daily Herald- WPhotos: Massive fire in Walthamwcvb.com
- Takeda deal affords ImmunoGen both cash and credibility boostbizjournals.com
- ImmunoGen hires former Shire, Genzyme exec as new CEObizjournals.com
- ImmunoGen axes 75% of staff to fund new clinical trialbizjournals.com
- MImmunoGen, Solid Biosciences and Insys lead Wednesday’s biotech losersmarketwatch.com
- Crash claims the life of Waltham manAustin Daily Herald
- Waltham 'microlocation' startup Humatics raises $28Mbizjournals.com